Cocaine Abuse in Schizophrenic Patients Treated With Olanzapine Versus Haloperidol
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Comorbid cocaine abuse adversely affects clinical outcomes in schizophrenia. Using a prospective, randomized, parallel group design (N = 24), we tested the hypothesis that patients with schizophrenia treated with olanzapine have reduced cocaine craving and abuse compared with those treated with haloperidol. In addition, we examined whether this differential effect correlated with reductions in extrapyramidal symptoms, positive and negative symptoms, and/or depression. There were no significant differences overall in proportions of positive drug screens between treatment groups; no differences in positive, negative, or depressive symptoms; and few differences between treatment conditions in extrapyramidal symptoms. However, craving for cocaine was rated significantly lower by patients treated with haloperidol compared with patients treated with olanzapine. Important study limitations include a small sample size and high attrition rates. Larger controlled studies are necessary to determine optimal antipsychotic therapy for patients with schizophrenia and comorbid cocaine abuse.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Goldstein, R. Z., & Volkow, N. D. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.10.1642 · Cited by 2,667 · cited 2×
“Several lines of evidence have implicated mesolimbic and mesocortical dopamine systems in drug reward circuits (Bronstein and Cummings, 2001; Capote et al., 2001; Goldstein and Volkow, 2002).”
BackgroundDrug abuse in schizophrenic patients: clinical correlates and reasons for use
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.2.224 · Cited by 547 · cited 2×
“…on EPS compared with conventional agents (Beasley et al., 1996a, 1996b; Collaborative Working Group on Clinical Trial Evaluations, 1998; DeQuardo et al., 1994; Dixon et al., 1991; Leucht et al., 1999; Regier et al., 1984; Roberts and Vickers, 1984; Seibyl et al., 1993; Tollefson et al., 1997).”
BackgroundInfluential
Cited by
Lingford-Hughes, A., Welch, S., Peters, L., Nutt, D., & With expert reviewers (in alphabetical order): Ball D, B. N. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112444324 · Cited by 332
“In other small trials, no clinically meaningful differences were found, (Sayers et al., 2005; Smelson et al., 2006) (Ib).”
BackgroundTreatment of substance abusing patients with comorbid psychiatric disorders
Kelly, T. M., Daley, D. C., & Douaihy, A. B. (2012) · Addictive Behaviors · doi:10.1016/j.addbeh.2011.09.010 · Cited by 284
The link between schizophrenia and substance use disorder: A unifying hypothesis
Khokhar, J. Y., Dwiel, L. L., Henricks, A. M., Doucette, W. T., & Green, A. I. (2018) · Schizophrenia Research · doi:10.1016/j.schres.2017.04.016 · Cited by 281
Bentzley, B. S., Han, S. S., Neuner, S., Humphreys, K., Kampman, K. M., & Halpern, C. H. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.8049 · Cited by 161
Torrens, M., Rossi, P. C., Martinez-Riera, R., Martinez-Sanvisens, D., & Bulbena, A. (2012) · Substance Use & Misuse · doi:10.3109/10826084.2012.663296 · Cited by 122
Metadata
- Authors
- Sayers, S. L., Campbell, E. C., Kondrich, J., Mann, S. C., Cornish, J., O'Brien, C., & Caroff, S. N.
- Venue
- Journal of Nervous & Mental Disease
- Published
- 2005-06
- Volume
- 193
- Issue
- 6
- Pages
- 379-386
- ISSN
- 0022-3018 (ISSN-L)
- OpenAlex
- W2018279494
- Cited by
- 68
- References
- 2
- FWCI
- 3.30
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cocaine Abuse in Schizophrenic Patients Treated With Olanzapine Versus Haloperidol. https://app.cochat.ai/papers/10.1097/01.nmd.0000165089.14736.bf
- The paper
- Sayers, S. L., Campbell, E. C., Kondrich, J., Mann, S. C., Cornish, J., O'Brien, C., & Caroff, S. N. (2005). Cocaine Abuse in Schizophrenic Patients Treated With Olanzapine Versus Haloperidol. Journal of Nervous & Mental Disease. https://doi.org/10.1097/01.nmd.0000165089.14736.bf
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.